A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
This will be an open-label, phase 2 study in which subjects will receive ISA101b and cemiplimab.
Squamous Cell Carcinoma of the Oropharynx
DRUG: ISA101b
Objective Response Rate based on radiographic response, Measured by RECIST version 1.1., 20-25 monhts
This study will assess the ability of ISA101b plus cemiplimab to improve Overall Response Rate in subjects who have progressed on prior anti-PD-1 therapy.